G3BP2 regulated by the IncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript

Yinli Zheng1,2,8, Jinjun Wu3,8, Ru Deng1,2,8, Censhan Lin1,2,8, Yuhua Huang1,2, Xia Yang1,2, Chunhua Wang3,1,2, Mingming Yang1,2, Yangfan He1,2, Jiabin Lu1,2, Xiaodong Su1,4, Qian Yan5, Yinghui Zhu6,7, Yan Li1,2,8 and Jingping Yun1,2,8

Metastasis is the leading cause of death of patients with esophageal squamous cell carcinoma (ESCC). Although an increasing number of studies have demonstrated the involvement of G3BP2 in several human cancers, how G3BP2 interacts with long noncoding RNAs and regulates mRNA transcripts in mediating ESCC metastasis remains unclear. In this study, we uncovered that G3BP2 was upregulated in ESCC. Further analysis revealed that upregulation of G3BP2 was significantly correlated with lymph node metastasis, depth of tumor invasion and unfavorable outcomes in ESCC patients. Both in vitro and in vivo functional assays demonstrated that G3BP2 dramatically enhanced ESCC cell migration and invasion. Mechanistically, LINC01554 maintained the high G3BP2 expression in ESCC by protecting G3BP2 from degradation through ubiquitination and the interaction domains within LINC01554 and G3BP2 were identified. In addition, RNA-seq revealed that HDGF was regulated by G3BP2. G3BP2 bound to HDGF mRNA transcript to stabilize its expression. Ectopic expression of HDGF effectively abolished the G3BP2 depletion-mediated inhibitory effect on tumor cell migration. Intriguingly, introduction of compound C108 which can inhibit G3BP2 remarkably suppressed ESCC cell metastasis in vitro and in vivo. Collectively, this study describes a newly discovered regulatory axis, LINC01554/G3BP2/HDGF, that facilitates ESCC metastasis and will provide novel therapeutic strategies for ESCC.

Oncogene (2022) 41:515–526; https://doi.org/10.1038/s41388-021-02073-0

INTRODUCTION

Esophageal carcinoma (EC) is an exceedingly aggressive cancer with a high mortality rate and poor prognosis worldwide [1], and squamous cell carcinoma is the major pathological type of EC [2]. Clinically, metastasis is the ultimate challenge for effectively treating ESCC. The lymph nodes and lung are the most frequent metastatic organs. To date, although several whole-exon sequencing studies have identified universally mutated genes that illustrate the genetic alterations in patients with ESCC [3–5] and lots of research on ESCC metastasis have been carried out [6, 7], the precise molecular mechanisms and complexity of ESCC metastasis are still not fully understood. Thus, discovering the mechanisms of the dissemination ESCC cells will be valuable for the development of novel therapeutic approaches for ESCC.

Ras-GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2) is located on the long arm of chromosome 4 (4q21), which has been reported to harbor genetic variant risk factors for ESCC in the Chinese population [8]. G3BP2 is mainly distributed in the cytoplasm and participates in the formation of stress granules [9], cell differentiation, proliferation, and signal transduction [10]. Accumulating evidence has demonstrated that aberrant expression of G3BP2 contributes to cancer initiation and progression, such as high expression of G3BP2 increasing cell stemness, metastasis and chemoresistance in breast cancer [11–13], upregulation of G3BP2 promoting cell growth and survival in prostate cancer [14], and bladder cancer [15]. In addition, G3BP2 attenuates the effectiveness of radiation in the treatment of oral cancer [16]. However, the function and mechanism of G3BP2 in ESCC metastasis have yet to be elucidated.

G3BP2 belongs to the G3BP protein family, which has four distinct motifs in its protein structure, including a nuclear transport factor 2-like domain, acidic and proline-rich regions, an RNA recognition motif (RRM) and an arginine and glycine rich box (RGG box). Among the motifs, the RRM domain is the most common specific basic domain of RNA binding proteins (RBPs) [17]. Mounting evidence has revealed that RBPs engage in posttranscriptional regulation by modulating RNA splicing, polyadenylation, mRNA stability, mRNA localization, and translation through interacting with coding or noncoding RNAs and regulates mRNA transcripts in mediating ESCC metastasis remains unclear. In this study, we uncovered that G3BP2 was upregulated in ESCC. Further analysis revealed that upregulation of G3BP2 was significantly correlated with lymph node metastasis, depth of tumor invasion and unfavorable outcomes in ESCC patients. Both in vitro and in vivo functional assays demonstrated that G3BP2 dramatically enhanced ESCC cell migration and invasion. Mechanistically, LINC01554 maintained the high G3BP2 expression in ESCC by protecting G3BP2 from degradation through ubiquitination and the interaction domains within LINC01554 and G3BP2 were identified. In addition, RNA-seq revealed that HDGF was regulated by G3BP2. G3BP2 bound to HDGF mRNA transcript to stabilize its expression. Ectopic expression of HDGF effectively abolished the G3BP2 depletion-mediated inhibitory effect on tumor cell migration. Intriguingly, introduction of compound C108 which can inhibit G3BP2 remarkably suppressed ESCC cell metastasis in vitro and in vivo. Collectively, this study describes a newly discovered regulatory axis, LINC01554/G3BP2/HDGF, that facilitates ESCC metastasis and will provide novel therapeutic strategies for ESCC.

Oncogene (2022) 41:515–526; https://doi.org/10.1038/s41388-021-02073-0

INTRODUCTION

Esophageal carcinoma (EC) is an exceedingly aggressive cancer with a high mortality rate and poor prognosis worldwide [1], and squamous cell carcinoma is the major pathological type of EC [2]. Clinically, metastasis is the ultimate challenge for effectively treating ESCC. The lymph nodes and lung are the most frequent metastatic organs. To date, although several whole-exon sequencing studies have identified universally mutated genes that illustrate the genetic alterations in patients with ESCC [3–5] and lots of research on ESCC metastasis have been carried out [6, 7], the precise molecular mechanisms and complexity of ESCC metastasis are still not fully understood. Thus, discovering the mechanisms of the dissemination ESCC cells will be valuable for the development of novel therapeutic approaches for ESCC.

Ras-GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2) is located on the long arm of chromosome 4 (4q21), which has been reported to harbor genetic variant risk factors for ESCC in the Chinese population [8]. G3BP2 is mainly distributed in the cytoplasm and participates in the formation of stress granules [9], cell differentiation, proliferation, and signal transduction [10]. Accumulating evidence has demonstrated that aberrant expression of G3BP2 contributes to cancer initiation and progression, such as high expression of G3BP2 increasing cell stemness, metastasis and chemoresistance in breast cancer [11–13], upregulation of G3BP2 promoting cell growth and survival in prostate cancer [14], and bladder cancer [15]. In addition, G3BP2 attenuates the effectiveness of radiation in the treatment of oral cancer [16]. However, the function and mechanism of G3BP2 in ESCC metastasis have yet to be elucidated.

G3BP2 belongs to the G3BP protein family, which has four distinct motifs in its protein structure, including a nuclear transport factor 2-like domain, acidic and proline-rich regions, an RNA recognition motif (RRM) and an arginine and glycine rich box (RGG box). Among the motifs, the RRM domain is the most common specific basic domain of RNA binding proteins (RBPs) [17]. Mounting evidence has revealed that RBPs engage in posttranscriptional regulation by modulating RNA splicing, polyadenylation, mRNA stability, mRNA localization, and translation through interacting with coding or noncoding RNAs and regulates mRNA transcripts in mediating ESCC metastasis remains unclear. In this study, we uncovered that G3BP2 was upregulated in ESCC. Further analysis revealed that upregulation of G3BP2 was significantly correlated with lymph node metastasis, depth of tumor invasion and unfavorable outcomes in ESCC patients. Both in vitro and in vivo functional assays demonstrated that G3BP2 dramatically enhanced ESCC cell migration and invasion. Mechanistically, LINC01554 maintained the high G3BP2 expression in ESCC by protecting G3BP2 from degradation through ubiquitination and the interaction domains within LINC01554 and G3BP2 were identified. In addition, RNA-seq revealed that HDGF was regulated by G3BP2. G3BP2 bound to HDGF mRNA transcript to stabilize its expression. Ectopic expression of HDGF effectively abolished the G3BP2 depletion-mediated inhibitory effect on tumor cell migration. Intriguingly, introduction of compound C108 which can inhibit G3BP2 remarkably suppressed ESCC cell metastasis in vitro and in vivo. Collectively, this study describes a newly discovered regulatory axis, LINC01554/G3BP2/HDGF, that facilitates ESCC metastasis and will provide novel therapeutic strategies for ESCC.

Oncogene (2022) 41:515–526; https://doi.org/10.1038/s41388-021-02073-0
noncoding RNAs [18]. Therefore, RBPs are critical for maintaining the homeostasis of gene expression. Abnormal expression of RBPs disrupts gene expression homeostasis and causes human diseases, especially cancers. As RBPs, G3BPs have been reported to participate in the regulation of gene expression by modulating mRNA stability and translation under the stimulation of environmental stresses in several diseases, including cancer progression and virus survival [10]. Nevertheless, how G3BP2 interacts with mRNAs in ESCC remain to be explored.

Long noncoding RNAs (lncRNAs), transcribed RNAs of more than 200 nucleotides in length, engage in diverse biological processes involved in tumor initiation, growth and metastasis at the epigenetic, transcriptional, posttranscriptional, and translational levels [19]. LncRNAs has been reported to most frequently modulate the expression, conformation, and localization of target proteins [20]. In our study, both the RNA–protein interaction prediction platforms catRAPID (http://service.tartaglia-lab.com) and RPI-seq (http://pridb.gdcb.iastate.edu) suggest that G3BP2 may interact with the lncRNA LINC01554. LINC01554 is a long intergenic noncoding RNA and is mainly localized in the cytoplasm. It has been demonstrated to attenuate cell growth by inhibiting glycolytic effects [21] and acting as a miRNA sponge to interfere with NGFR expression in hepatocellular carcinoma (HCC) [22]. However, the role of LINC01554 in ESCC and how LINC01554 modulates G3BP2 have not been fully illustrated.

In this study, our data revealed that G3BP2 was frequently upregulated in ESCC tissues and predicted unfavorable patient outcomes. Mechanistically, LINC01554 maintained the high

**Fig. 1** Upregulation of G3BP2 is correlated with unfavorable outcome in ESCC patients. A Big data mining from Oncomine (https://www.oncomine.org) and TCGA (https://www.cancer.gov) showed that G3BP2 was upregulated in ESCC. B mRNA expression of G3BP2 was examined by RT-qPCR using SYSUCC samples. GAPDH served as an internal control. C The protein expression of G3BP2 in immortalized esophageal epithelium cells (NE1) and ESCC cell lines. GAPDH acted as a loading control. D Representative images of G3BP2 staining in nontumor tissue and ESCC tissue microarray by immunohistochemistry analysis. Scale bar, up: 100 μm, down: 50 μm. E IHC score of G3BP2 staining in ESCCs and corresponding nontumor samples (n = 93). F and G Clinicopathologic correlation analyses of G3BP2 expression in ESCC. H Correlation between G3BP2 expression and overall survival was analyzed in the SYSUCC cohort by Kaplan-Meier curve analysis.

Y. Zheng et al. Oncogene (2022) 41:515 – 526
expression of G3BP2 by inhibiting ubiquitin mediated proteasome degradation of G3BP2. RNA-seq further identified hepatoma-derived growth factor (HDGF) as the objective mRNA that regulated by G3BP2. G3BP2 stabilized HDGF mRNA transcript to maintain its high expression level and then increased ESCC metastasis. Notably, the introduction of compound C108, a small molecule that inhibits G3BP2, markedly attenuated ESCC cell metastasis in vitro and in vivo. In conclusion, our findings...
describe a new regulatory signaling axis, LINC01554/G3BP2/HDF, that facilitates ESCC metastasis, and highlight that G3BP2 could be a promising therapeutic target for treatment of ESCC.

RESULTS

Upregulation of G3BP2 is correlated with unfavorable outcomes in ESCC patients

To investigate the expression status of G3BP2 in ESCC, we first performed big data mining from Oncomine (https://www.oncomine.org) and TCGA databases (https://www.cancer.gov) Both databases indicated that G3BP2 was highly expressed in ESCC (Fig. 1A), which was further confirmed in the SYSUCC cohort at both the mRNA (Fig. 1B) and protein levels (Supplementary Fig. 1). Elevated expression of G3BP2 was also detected by Western blot analysis in ESCC cells (Fig. 1C). To investigate the clinical significance of upregulated G3BP2 expression in ESCC, a tissue microarray containing 183 primary ESCCs and 93 paired nontumor tissues was studied by IHC staining (Fig. 1D). The result indicated the high expression of G3BP2 in ESCC tissues (P < 0.0001, Fig. 1E). Furthermore, high G3BP2 expression was significantly associated with lymph node metastasis (P = 0.009, Fig. 1F) and the depth of tumor invasion (P < 0.001, Fig. 1G, Supplementary Table 1). Kaplan-Meier analysis demonstrated that high G3BP2 expression contributed to poorer overall survival of ESCC patients (P = 0.02, Fig. 1H). All these data illustrate the robustness of the correlation between high G3BP2 expression levels and ESCC progression.

LINCO1554 protects G3BP2 from ubiquitin-proteasome degradation

According to the structural characteristics of G3BP2, which harbors an RNA recognition motif, we asked whether it interacted with noncoding RNAs. Both the catRAPID and RPI-seq platforms strongly suggested the possibility of an interaction between G3BP2 and LINCO1554 (Fig. 2A, B). Then, RNA FISH-IF, RIP, and RNA pull-down assays were conducted to validate the prediction results. The results of the RNA FISH-IF assay showed that G3BP2 and LINCO1554 colocalized in the cytoplasm (Fig. 2C). RIP assay presented that G3BP2 could specifically precipitate LINCO1554 (Fig. 2D). RNA pull-down assays further demonstrated that the LINCO1554 probe, but not its antisense probe, significantly pull down G3BP2 protein (Fig. 2E). In light of the accumulating evidence showing that lncRNAs may modulate their binding objects [19, 20], we examined whether LINCO1554 regulated G3BP2 expression. Both G3BP2 RNA and protein were detected in LINCO1554-transfected KYSE30 and KYSE150 cells, and we observed that G3BP2 was increased at protein level but not RNA level after transfection of LINCO1554 (Fig. 2F and Supplementary Fig. 2A, B). And silencing LINCO1554 declined G3BP2 protein expression (Supplementary Fig. 2C, D). Next, we explored how LINCO1554 increased G3BP2 protein expression. Since recent studies have illustrated that lncRNAs regulated the protein levels of their target genes by interfering with the protein stability [23, 24], a cycloheximide chase assay was carried out to verify our hypothesis. The results showed that the half-life of the G3BP2 protein was obviously longer in LINCO1554-transfected cells (Fig. 2G, left panel). To examine whether G3BP2 degradation occurred via the ubiquitin-mediated proteasome system, an in vitro ubiquitination assay was performed, and it was found that LINCO1554 decreased the level of G3BP2 ubiquitination (Fig. 2G, right panel). Moreover, the reduction of G3BP2 in LINCO1554 knockdown cells was rescued when treated with MG132 (Supplementary Fig. 2E). Therefore, these data show that LINCO1554 interacts with G3BP2 and protects it from protein degradation mediated by the ubiquitin-proteasome system.

To confirm that the RRM domain of G3BP2 directed the interaction with LINCO1554, we established G3BP2 mutants with deletion of the RRM domain. The results of the RIP (Fig. 2H) and RNA pull-down assays (Fig. 2I) demonstrated that the RRM domain of G3BP2 indeed bound to LINCO1554. However, we observed that in spite of deletion of RRM domain, there was still about 40% of LINCO1554 bound to G3BP2. To eliminate the possibility of other domains in G3BP2 interacted with LINCO1554, RIP assays were conducted in cells transfected with a series of truncation mutant constructs. The result showed that only removing RRM domain impaired the interaction between G3BP2 and LINCO1554 (Supplementary Fig. 2F). After elimination of the RRM domain, protein expression of G3BP2 was decreased due to enhanced protein degradation through ubiquitination (Fig. 2J–L). Next, we used catRAPID platform to predict the specific binding sequences within LINCO1554 that was essential for its interaction with G3BP2. The higher absolute value of interaction score indicated the greater possibility of the interaction. As Fig. 2M showed, nucleotide sequences of 1–600 bp presented low interaction score, while that of 600–800 bp displayed the highest interaction score. Sequences of 1400–1931 bp also presented the relatively high interaction score. According to the above result and considering the length of secondary structure of LINCO1554, the

Fig. 2 LINCO1554 protects G3BP2 from ubiquitin-proteasome degradation. A catRAPID (http://service.tartaglialab.com) suggested the interaction between G3BP2 and LINCO1554. B RPI-seq platforms (http://pridb.gdcb.iastate.edu) strongly recommended the possibility of interaction between G3BP2 and LINCO1554. C Colocalization of G3BP2 and LINCO1554 was detected by FISH-IF. Scale bar, 20 μm. RIP (D) and RNA pull-down (E) assays showed the interaction of G3BP2 with LINCO1554. IgG antibody served as a control for RIP assay. F Western blot analysis revealed that the protein expression of G3BP2 was upregulated by LINCO1554 in LINCO1554-transfected KYSE30 and KYSE150 cells. G Cycloheximide chase assay showed that the half-life of the G3BP2 protein in LINCO1554-transfected KYSE30 cells was longer than that in empty vector cells (left). In vitro ubiquitination assay showed that the ubiquitination level of the G3BP2 protein was abolished in LINCO1554-transfected KYSE30 cells (right). RIP (H) and RNA pull-down (I) assays showed that G3BP2 did not bind to LINCO1554 after deletion of the RRM domain in G3BP2. IgG antibody served as a control for the RIP assay. FL-G3BP2, full-length G3BP2; AARM-G3BP2, truncation of the RRM domain in G3BP2. J Western blot showed that the G3BP2 protein level was decreased in KYSE30 cells with truncation of the RRM domain. K Cycloheximide chase assay showed that the half-life of the G3BP2 protein was shorter in KYSE30 cells with truncation of the RRM domain than in cells with full-length G3BP2. L In vitro ubiquitination assay showed that the ubiquitination level of the G3BP2 protein was dramatically increased in KYSE30 cells with truncation of the RRM domain. M catRAPID platform (http://service.tartaglialab.com) was applied to predict the specific binding sequence of LINCO1554 with G3BP2 protein. N Top, schematic structures showing a summary of in vitro transcribed, biotinylated full-length, truncated or antisense LINCO1554 probes. Bottom, immunoblot analysis with anti-G3BP2 in KYSE30 cells followed by RNA pull-down assay with full-length, truncated or antisense LINCO1554 probes. FL, full length (1–1931 bp); F1, fragment 1 (1–500 bp); F2, fragment 2 (400–900 bp); F3, fragment 3 (1400–1931 bp); AS, antisense. RIP (O) and RNA pull-down (P) assays showed that the interaction of G3BP2 and LINCO1554 was weakened in KYSE30 cells transfected with truncated fragment 2 in LINCO1554. IgG antibody served as a control for RIP assay. Q Western blot showed that the G3BP2 protein level declined in KYSE30 cells transfected with truncated fragment 2 within LINCO1554. R Cycloheximide chase assay showed that the half-life of the G3BP2 protein with truncated fragment 2 in LINCO1554-transfected KYSE30 cells was shorter than that in full-length transfected cells (left). In vitro ubiquitination assay showed that the ubiquitination level of the G3BP2 protein was elevated in KYSE30 cells transfected with LINCO1554 with fragment 2 truncated (right). The data represent the mean ± SD from three biological replicates. **P < 0.01, ***P < 0.001.
actual binding sequences of LINC01554 with G3BP2 might range from 400–900 bp. Thereafter, we constructed and biotinylated three truncated fragments of LINC01554 (fragment 1: 1–500 bp, fragment 2: 400–900 bp, fragment 3: 1400–1931 bp) for use in an RNA pull-down assay with KYSE30 cell lysates, and found that fragment 2 of LINC01554 indeed pulled down G3BP2, but not other fragments (Fig. 2N). To further examine the indispensable function of fragment 2 in LINC01554 interacting with G3BP2, a LINC01554 mutant with a fragment 2 deletion was constructed. The results of the RIP and RNA pull-down assays revealed the
Fig. 3 G3BP2 enhances ESCC cell metastasis in vitro and in vivo. A The ectopic expression and knockdown efficiency of G3BP2 were detected by Western blot. B Transwell assays revealed that ectopic expression of G3BP2 enhances cell migration and invasion in KYSE410 and KYSE510 cells. Scale bar, 50 μm. Data are presented as the mean ± SD of three biological replicates. C Wound healing assay showed that silencing G3BP2 significantly impaired cell migration in KYSE30 and KYSE150 cells. Representative images were captured 24 h after scratching. D Transwell assays showed that knocking down G3BP2 attenuated the migration and invasion capability of KYSE30 and KYSE150 cells. Scale bar, 50 μm. The data are expressed as the mean ± SD of three biological replicates. E An in vivo inguinal lymph node metastatic model showed smaller size and lighter weight of lymph nodes with weak G3BP2 staining in the G3BP2-knockdown group compared with metastatic lymph nodes in the control group (n = 5 mice/group of KYSE30 cells, n = 6 mice/group of KYSE150 cells). Scale bar, 50 μm. F In vivo lung metastatic model via tail venous injection presented fewer metastatic nodules under a microscope and weaker G3BP2 staining by IHC in the G3BP2 silenced group (n = 6 mice/group). Black arrows indicate metastatic nodules formed in the lung. Scale bar, 50 μm. The data represent the mean ± SD. *P < 0.05, **P < 0.01.

G3BP2 enhances ESCC cell metastasis in vitro and in vivo

Given the clinical significance and mechanism of elevated G3BP2 expression in ESCC, we next explored the roles of G3BP2 in ESCC progression. Above all, stable cell lines with ectopic expression or knockdown efficiency of G3BP2 were established in low endogenous G3BP2 expression cells (KYSE410 and KYSE10 cells) and high endogenous G3BP2 expression cells (KYSE30 and KYSE150 cells), respectively. The overexpressed and knockdown efficiency was examined by Western blot (Fig. 3A). Ectopic expression of G3BP2 in KYSE410 and KYSE10 cells dramatically increased ESCC cell migration and invasion (Fig. 3B), while knocking down G3BP2 in KYSE30 and KYSE150 cells remarkably attenuated cell metastatic ability (Fig. 3C, D), but did not affect cell growth (Supplementary Fig. 2G). Collectively, these findings show that LINC01554 binds to the RRM domain of G3BP2 mainly through the nucleotide domain ranging from 400 to 900 bp.

G3BP2 stabilizes HDGF mRNA transcript

To identify the mRNA transcripts regulated by G3BP2 involved in inducing ESCC metastasis, we carried out RNA-seq on G3BP2-knockdown KYSE30 and KYSE150 cells. Based on the filtering criteria of P < 0.05 and log2 (fold change) > 1, 387 and 263 differentially downregulated genes were identified in KYSE30 cells and KYSE150 cells, respectively, among which 25 genes were shared in both cell lines (Fig. 4A). By combining the fold change and significant P value results, we found that HDGF presented a large fold change with a very significant P value in both KYSE30 and KYSE150 cells among the top 10 differentially downregulated genes (Fig. 4B). In particular, accumulating studies have shown that HDGF plays an important role in driving tumor cell metastasis [25].

To validate the RNA-seq result, we detected both the RNA and protein levels of HDGF in stable G3BP2-knockdown cell lines and found that they were significantly decreased compared with those in control cells (Fig. 4C). IHC staining analysis also showed the low expression of HDGF in metastatic lymph nodes and lung tissue derived from G3BP2-knockdown KYSE150 cells (Fig. 4D). We next sought to figure out how G3BP2 modulated HDGF expression. G3BP2 belongs to class of RNA binding proteins and has been reported to stabilize the SART3 mRNA transcript through its RNA binding domain [11]. Based on that, we deduced G3BP2 regulates HDGF expression by similar mechanisms. A RIP assay was performed to verify our speculation and found that G3BP2 is indeed bound to HDGF mRNA transcript (Fig. 4E). Next, the mRNA half-life assay revealed that silencing G3BP2 led to a significant reduction of the HDGF mRNA stability (Fig. 4F). To examine whether G3BP2 interacted with HDGF through RRM domain, RIP assay and RNA stability assay were further performed in RRM domain truncated- and empty vector- cells. We found that HDGF mRNA enrichment and RNA stability were significant decreased in cells with the deleted RRM domain (Supplementary Fig. 4A, B). Finally, to clarify the correlation between G3BP2 and HDGF expression in ESCC, we first explore the expression status of HDGF in ESCC using public data (http://ualcan.path.uab.edu) and the result revealed that HDGF was upregulated in ESCC (Supplementary Fig. 4C), which was consistent with the expression status of G3BP2 in ESCC. Then, we detected the RNA expression levels of HDGF and HDGF in an SYSUCC cohort of 34 ESCC samples, and found that the expression of G3BP2 and HDGF was positively correlated (P < 0.0001, Fig. 4G). These findings suggest that G3BP2 modulates HDGF expression by stabilizing its mRNA transcript.

The LINC01554/G3BP2/HDGF signaling axis facilitates ESCC cell metastasis

Given that LINC01554 controlled the protein stability of G3BP2 and HDGF mRNA transcript was regulated by G3BP2, we then investigated whether the LINC01554/G3BP2/HDGF regulatory signaling axis played a critical role in driving ESCC metastasis. First, the effect of the interaction between G3BP2 and LINC01554 in ESCC metastasis was validated by migration and invasion transwell assays. The results showed that elimination of either the RRM domain in G3BP2 or fragment 2 within LINC01554 in KYSE30 cells significantly attenuated cell migration and invasion (Fig. 5A, B). However, the expression status and function of LINC01554 in ESCC were still confusing. The RT-qPCR results showed that LINC01554 was highly expressed in ESCC (Supplementary Fig. 5A). Transwell assay presented that overexpressing LINC01554 increased ESCC cell migratory and invasive abilities (Supplementary Fig. 5B), while silencing LINC01554 dramatically attenuated the migration of ESCC cells (Supplementary Fig. 5C). To confirm that G3BP2 mediated LINC01554-facilitated ESCC cell metastasis, G3BP2 was then silenced in LINC01554-transfected KYSE30 cells. We found that G3BP2 protein expression was markedly decreased (supplementary Fig. 5D, Fig. 5C) and that cell metastasis was abolished (Supplementary Fig. 5E, Fig. 5D). Besides, overexpression of G3BP2 in LINC01554-knockdown cells significantly eliminated the metastasis-suppressive function upon LINC01554 silencing (Supplementary Fig 5F). Moreover, induced expression of LINC01554 reversed G3BP2 expression (Supplementary Fig. 5G, Fig. 5E) and functionally rescued the decrease in cell migration and invasion upon G3BP2 silencing (Supplementary Fig. 5H, Fig. 5F). Considering that HDGF was regulated by G3BP2, we detected the expression of HDGF in KYSE30
cells after transfection of LINC01554 or release of the interaction between LINC01554 and G3BP2. The results showed that HDGF expression was elevated after ectopically expressing LINC01554 but decreased when the domain responsible for the interaction between LINC01554 and G3BP2 was deleted (Fig. 5G). To elucidate the pivotal role of HDGF in the G3BP2 mediated ESCC metastasis, we expressed HDGF in G3BP2-knockdown cells and found that the protein expression of HDGF was rescued (Fig. 5H). Transwell migration assay showed that overexpressing HDGF promoted ESCC cell migration and effectively rescued the reduction in cell migration induced by silencing G3BP2 (Fig. 5I). Conversely, knocking down HDGF remarkably inhibited cell migration and abolished the metastasis-promoting role of G3BP2 (Supplementary Fig. 5I). Eventually, we detected the expression of LINC01554 with RNA FISH and expression of G3BP2 as well as HDGF with IHC staining in three pairs of ESCC and nontumor samples, and observed that the expression of LINC01554, G3BP2, and HDGF showed the same pattern. High expression of LINC01554 was observed with increased...
G3BP2 and HDGF expression in ESCC, while low expression of LINC01554 was observed with decreased expression of G3BP2 and HDGF in corresponding nontumor tissues (Fig. 5J). Taken together, our results indicate the essential role of the LINC01554/G3BP2/HDGF signaling axis in facilitating ESCC metastasis.

A G3BP2 inhibitor compound C108 effectively abrogates ESCC cell metastasis in vitro and in vivo
Compound C108, a small molecule that inhibits several proteins including G3BP2, was developed by Nisha Gupta et al. in 2017. It was reported to block the RRM domain and then impaired the
stability of SART3 mRNA, subsequently leading to tumor suppression in breast cancer [11]. To test whether compound C108 could abrogate the interaction between G3BP2 and LINC0154 and potentially be used to block ESCC metastasis induced by G3BP2, we first treated G3BP2-overexpressing KYSE410 cells, LINC0154-transfected KYSE30 cells with compound C108 and corresponding control cells, and then observed the G3BP2 expression and tumor cell metastatic abilities. Western blot showed that the expression of G3BP2 was dramatically diminished in cells treated with compound C108 (Supplementary Fig. 6A, C and Fig. 6B). Due to reduced G3BP2 expression, both tumor cell migration and invasion were inhibited (Supplementary Fig. 6B, C and Fig. 6B). To further confirm the suppressive effect of compound C108 on G3BP2 expression and tumor cell metastasis, we introduced compound C108 to KYSE30 and KYSE150 cells, which had high expression of endogenous G3BP2. A reduction of G3BP2 expression, tumor cell migration, and invasion were also observed in cells treated with compound C108 (Fig. 6C, D). Moreover, in mouse model of lymph node metastasis derived from LINC0154-transfected KYSE30 cells, KYSE30, and KYSE150 cells respectively, we found compared with the vehicle control group, metastatic lymph nodes in compound C108 treatment group were smaller in size and lighter in weight (Fig. 6E-G). Metastatic lymph node sections subjected to G3BP2 and HDGF staining displayed significantly decreased expression of either G3BP2 or HDGF in the group treated with compound C108 compared with that in the control group (Fig. 6H). To further confirm that compound C108 interrupted the interaction of G3BP2 and LINC0154 by blocking RRM domain, RNA pull-down assays were conducted in KYSE30 cells treated with DMSO and compound C108. However, no significant changes of G3BP2 pulled down by LINC0154 were found (Supplementary Fig. 6D). We then wonder if compound C108 could regulate the expression of LINC0154, G3BP2 and HDGF. qRT-PCR was performed, and unexpectedly, all of them were decreased after treated compound C108 in KYSE30 and KYSE150 cells (Supplementary Fig. 6E), which indicated that compound C108 might exert the metastasis-suppressive functions through targeting various genes. Both downregulation of LINC0154 and G3BP2 would decrease the G3BP2 protein level and subsequently diminished the expression of HDGF. Taken together, these results suggest that compound C108 may be used as a promising treatment for metastatic ESCC.

**DISCUSSION**

In this study, we revealed that G3BP2 was frequently upregulated in ESCC and was associated with lymph node metastasis, the depth of tumor invasion, and unfavorable outcomes in ESCC patients. Functionally, G3BP2 significantly increased the migration and invasion of ESCC cells but did not affect ESCC cell growth. The role of G3BP2 as an oncogene in ESCC was characterized.

In addition to that in ESCC, we also detected the expression of G3BP2 in other types of squamous cell carcinoma, including lung squamous cell carcinoma (LUSC) and head and neck squamous cell carcinoma (HNSCC). We observed that G3BP2 was also highly expressed in both LUSC and HNSCC (Supplementary Fig. 7). These results strongly suggested that G3BP2 could be a general diagnostic biomarker and therapeutic target in squamous cell carcinoma. However, whether the functions and mechanisms of G3BP2 in LUSC and HNSCC are the same as those in ESCC deserves further investigations.

An increasing number of studies have revealed the molecular mechanism of G3BP2 in promoting cancer progression. For example, the loss of G3BP2 has been shown to promote nuclear translocation of TWIST1 with increasing matrix stiffness to drive epithelial-mesenchymal transition (EMT) tumor invasion and metastasis in breast cancer [12]. In line with the results of the above study, G3BP2 has been shown to be a treatment target in mesenchymal-like cisplatin-resistant TNBC cells, which drives S/G2 cell cycle progression to inhibit the cell response to cisplatin [13]. In addition, G3BP2 has been indicated to promote resistance to androgen deprivation therapy in prostate cancer by increasing nuclear export of P53 [14]. Besides, circFNDC3B competitively binds to miR-1178-3p, resulting in decreased expression of G3BP2, and then inhibits the downstream SRC/FAK signaling pathway to impair tumor growth and lymphatic metastasis in bladder cancer [15]. Here, we found that G3BP2 was protected by LINC0154 from ubiquitin-mediated protein degradation and stabilized HDGF mRNA transcripts to drive ESCC metastasis, which has not yet been reported during cancer progression.

So far, some mechanisms for regulating G3BP2 expression have been described. At the RNA level, G3BP2 is upregulated by androgen [14], miR-1178-3p [15], and the transcription factor FOXD1 [16]. At the protein level, the protein expression of G3BP2 is maintained by USP10 [26]. Nonetheless, how G3BP2 interacts with long noncoding RNAs has not been fully elucidated. In silico prediction suggested that G3BP2 might interact with the long noncoding RNA LINC0154. In our previous study, LINC0154 was shown to suppress tumor growth by impairing the cellular glycolytic effect in hepatocellular carcinoma [21]. However, here, our data showed that LINC0154 expression was elevated in ESCC and promoted cell migration and invasion by protecting the G3BP2 protein from proteasomal degradation. These findings suggest that LINC0154 may play various roles through distinct mechanisms in different cancers. Furthermore, according to the structural characteristics of G3BP2 and the G3BP2-binding region in LINC0154 predicted by catRAPID, we constructed plasmids with deletion of interactive regions within G3BP2 and LINC0154 and then performed a series of rescue experiments. The result revealed that G3BP2 interacted with nucleotide sequences ranging from 400 bp to 900 bp within LINC0154 through the
RRM domain. As to the result that deletion of other domains of G3BP2 increased the interaction between G3BP2 and LINC01554, the conformation changes of G3BP2 after removing part of domains may explain it [27, 28]. Regarding the specific mechanisms by which LINC01554 stabilizes the G3BP2 protein, we speculate that LINC01554 may work as a scaffold for G3BP2 and deubiquitinase in stress granules since G3BP2 has been reported to interact with a deubiquitinase, USP10, in that compartment [26]. On the other hand, the binding of LINC01554 with G3BP2 may trigger the conformation changes of G3BP2, thereby evading the recognition of ubiquitinases [29, 30].

In contrast to G3BP1, which has been reported to degrade c-Myc BART, and CTNNB1 mRNA transcripts, thereby promoting cancer cell growth, metastasis and invasion [31–33], and to sequester HIV-1 by inhibiting the translation and protein packaging of viral protein [34], only the SART3 mRNA transcript
has been shown to be stabilized by G3BP2, resulting in the elevated expression of pluripotent transcription factors in breast cancer initiation [11]. Thus, more RNA transcripts modulated by G3BP2 remain to be identified. Herein, the result of RNA-seq analysis highly recommended that HDGF might be regulated by G3BP2. Notably, HDGF has been shown to facilitate cell metastasis in lung cancer, Ewing sarcoma, HCC, and gastric cancer through activating EMT signaling or promoting actin cytoskeleton remodeling and cell-matrix adhesion [35–38]. We further showed that G3BP2 bound to the HDGF mRNA transcript through RRM domain and subsequently stabilized its expression in ESCC. Since HDGF and LINC01554 were both interacted with G3BP2 through RRM domain of G3BP2, whether HDGF and LINC01554 competed with each other was also investigated. Our data indicated that more HDGF transcript was enriched by anti-G3BP2 antibody after silencing LINC01554 and vice versa (Supplementary Fig. 8). Thus, in the current study, that HDGF and LINC01554 competitively interacted with G3BP2 at the same time was clarified.

To better understand the pivotal role of the LINC01554/G3BP2/HDGF signaling axis in facilitating ESCC metastasis, we designed and conducted a series of rescue experiments. The results showed that disrupting the interaction between G3BP2 and LINC01554 significantly downregulated HDGF expression and subsequently attenuated ESCC cell migration and invasion. In addition, both ectopic overexpression of LINC01554 and HDGF effectively restored the inhibitory effect of G3BP2 silencing on ESCC cell metastasis. Moreover, we found that the staining pattern of LINC01554, G3BP2, and HDGF was the same in ESCC and matched nontumor samples, which was in line with the results of the functional assays observed in vitro.

To explore whether G3BP2 is a promising therapeutic target for metastatic ESCC, a small molecule that inhibits G3BP2, compound C108, was exploited in this study. Compound C108 has been proven to inhibit tumor initiation in breast cancer in vitro and in vivo [11]. It mainly acts on the RRM domain to block the motif from binding to other molecules. However, here, we found that compound C108 inhibited G3BP2 expression not by hampering the interaction of G3BP2 and LINC01554 through RRM domain, but downregulated the RNA expression of LINC01554, G3BP2, and HDGF. Due to reduction of LINC01554, G3BP2 lost its protection from ubiquitin degradation. On the other hand, compound C108 directly declined the RNA level of G3BP2. As a molecular regulated by G3BP2, HDGF was also decreased by compound C108. But it is difficult to determine whether the reduction of HDGF is caused by decreased expression of G3BP2 or whether compound C108 directly regulates HDGF at RNA level. Hence, how compound C108 negatively regulate expression of LINC01554, G3BP2, and HDGF need to be further demonstrated in the future study. In addition, HDGF has been shown to promote tumor angiogenesis in oral cancer and HCC. In oral cancer, HDGF has been observed to induce VEGF gene expression by upregulating HIF-1α and NF-κB [39]. In HCC, HDGF antibodies obviously decrease tube formation by human umbilical vein endothelial cells [40]. Since angiogenesis is closely related to tumor metastasis, it can be a novel therapeutic strategy to combine compound C108 with antiangiogenic agents or antibodies against HDGF in the treatment of metastatic ESCC, which may achieve better treatment effects.

In conclusion, our findings (Fig. 6) identify a novel regulatory signaling axis, LINC01554/G3BP2/HDGF, that facilitates ESCC metastasis, which may provide rational strategies for developing potential biomarkers and therapeutic targets for ESCC.

MATERIALS AND METHODS
The materials and methods in detail were provided in the supplementary information file. The primer sequences are listed in Supplementary Table 2. The sequences of the shRNAs and siRNAs are listed in Supplementary Table 3.

DATA AVAILABILITY
All data generated/analyzed during this study are available from the corresponding author on reasonable request.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
2. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X. et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555–67.
3. Gao YB, Chen ZL, Li JG, Liu Y, Naxerova K, Sgroi D, Munn LL, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097–102.
4. Liu X, Zhang M, Ying S, Zhang C, Lin R, Zheng J, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology. 2017;155:163–77.
5. Chen XX, Zhong Q, Liu Y, Yan SM, Chen ZH, Jin SZ, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Nat Commun. 2017;8:534.
6. Hu X, Wu D, He X, Zhao H, He Z, Lin J, et al. circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Mol Cancer. 2019;18:160.
7. Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, et al. Circulating tumor dna analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 2020;158:494–505.
8. Gao Y, He Y, Xu J, Xu L, Du J, Zhu C, et al. Genetic variants at 4q21, 4q33 and 12q24 are associated with esophageal squamous cell carcinoma risk in a Chinese population. Hum Genet. 2013;132:649–56.
9. Matsuki H, Takahashi M, Higuchi M, Makokha GN, Oie M, Fuji M, et al. Both G3BP1 and G3BP2 contribute to stress granule formation. Genes Cells. 2013;18:135–45.
10. Alam U, Kennedy D, Raspuzin a decade on and more promising than ever? A review of G3BP1s. Biochim Biophys Acta Mol Cell Res. 2019;1866:360–70.
11. Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, et al. Stress granule-associated protein G3BP2 regulates breast tumor initiation. Proc Natl Acad Sci USA. 2017;114:1033–38.
12. Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat Cell Biol. 2015;17:678–88.
13. Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, et al. Modeling of cisplatin-induced signaling dynamics in triple-negative breast cancer cells reveals mediators of sensitivity. Cell Rep. 2019;28:2345–57.
14. Ashikari D, Takayama K, Tanaka TA-G, Suzuki Y, Obinata D, Fujimura T, et al. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer. Oncogene. 2017;36:6272–81.

15. Liu H, Bi J, Dong W, Yang M, Shi J, Jiang N, et al. Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the mir-17/5p-3p/G3BP2/SCF/FAK axis. Mol Cancer. 2020;19:124.

16. Lin CH, Lee HH, Chang WM, Lee FP, Chen LC, Lu LS, et al. Repression potentiates radiation effectiveness by downregulating expression and promoting the activation of related pathways in oral cancers. Cancer. 2020;12:2690.

17. Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3:506–28.

18. Dreyfuss G, Kim VN, Katoaka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol. 2002;3:195–205.

19. Yao RW, Wang Y, Chen LA-O. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21:542–51.

20. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63.

21. Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, et al. LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenesis in hepatocellular carcinoma via downregulating pkm2 expression and inhibiting akt/mtor signaling pathway. Theranostics. 2019;9:796–810.

22. Hao QY, Gao LH, Niu WY, Wang GJ, Zhang P, Chen L, et al. Long-chain non-coding RNA LINC01554 promotes NGFR expression and inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma by binding to microRNA-3681-3p. Eur Rev Med Pharm Sci. 2020;24:12667–74.

23. Tian H, Lian R, Li Y, Liu C, Liang S, Li W, et al. AKT-induced IncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation. Nat Commun. 2020;11:5127.

24. Wang Y, Lu JH, Wu QN, Jin Y, Wang DS, Chen YX, et al. LncRNA LINRIS stabilizes IGFB2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019;18:174.

25. Bao C, Wang J, Ma W, Wang X, Chen Y. HDGF: a novel jack-of-all-trades in cancer. Future Oncol. 2014;10:2675–85.

26. Takayama K, Suzuki T, Fujimura T, Takashashi S, Inoue S. Association of USP10 with G3BP2 inhibits p53 signaling and contributes to poor outcome in prostate cancer. Mol Cancer Res. 2018;16:846–56.

27. Hubner J-M, Müller T, Papageorgiou DN, Mauermann M, Krijgsfeld J, Russell RB, et al. EZH2/1:p53 heterodimers regulate cancer-related pathways in oral cancer. Cancers. 2020;12:2504.

28. Yuan Y, Zhang W, Yan R, Liao Y, Zhao L, Ruan C, et al. LncRNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SCF/FAK pathway. Mol Cancer. 2020;19:124.

29. Noh JH, Kim KM, Kwon J, et al. The LINK-A lncRNA activates normoxic HIF1α signaling in triple-negative breast cancer. Oncogene. 2021;40:731–45.

30. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, et al. The LINK-A lncRNA activates normoxic HIF1α signaling in triple-negative breast cancer. Oncogene. 2021;40:731–45.

31. Gallouzi IE, Parker F, Chebli K, Maurier F, Labourier E, Barlat I, et al. METTL3-mediated mRNA modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69:1193–205.

32. Lin YW, Huang ST, Wu JC, Chu TH, Huang SC, Lee CC, et al. Novel HDGF-HIF-1α/VEGF axis in oral cancer impacts disease prognosis. BMC Cancer. 2019;19:1083.

33. Bikkavilli RK, Malbon CC. Arginine methylation of G3BP1 in response to Wnt3a activation of β-catenin in breast cancer. Mol Cancer. 2017;16:846.

34. Valiente-Echeverria F, Melnychuk L, Vyboh K, Ajamian L, Gallouzi IE, Bernard N, et al. eIF2 and Ras-GAP SH3 domain-binding protein (G3BP1) modulate stress granule assembly during HIV-1 infection. Nat Commun. 2014;5:4819.

35. Fu Q, Song X, Liu Z, Deng X, Luo R, Ge C, et al. mRNomics and proteomics reveal a miR-296-3p/miR1248/Rasa1/c-Myc feedback loop modulated by HDGF/DDX5/β-catenin complex in lung adenocarcinoma. Clin Cancer Res. 2017;23:6336–50.

36. Yang Y, Ma Y, Gao H, Peng T, Shi H, Tang Y, et al. A novel HDGF–ALCAM axis activates the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway. Oncogene. 2021;40:731–45.

37. Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, et al. Mi6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020;13:5.

38. Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated mRNA modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69:1193–205.

39. Lin YW, Huang ST, Wu JC, Chu TH, Huang SC, Lee CC, et al. Novel HDGF-HIF-1α/VEGF axis in oral cancer impacts disease prognosis. BMC Cancer. 2019;19:1083.

40. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, et al. MicroRNA-214 down-regulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 2012;57:584–91.